Natural history and real-world treatment outcomes for non-small cell lung cancer patients with EGFR Exon 20 Insertion Mutation: An IASLC- ASCO CancerLinQ Study

Epidermal Growth Factor Receptor (EGFR) exon 20 insertion (ex20ins) mutations account for approximately 10% of EGFR mutations in lung adenocarcinoma. Patients with ex20ins mutation do not respond to standard EGFR TKI therapy. In this work, we analyzed the characteristics, treatment patterns and outcomes in this subgroup of NSCLC patients.